The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Open accessAbstract
Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor itself, but the immune system combating the cancerous lesion. Of the many approaches currently under study to boost anti-tumor immune responses; modulation of immune co-receptors on lymphocytes in the tumor microenvironment has thus far proven to be the most effective. Antibody blockade of the T cell co-inhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) has become the first FDA approved immune checkpoint blockade; however, tumor infiltrating lymphocytes express a diverse array of additional stimulatory and inhibitory co-receptors, which can be targeted to boost tumor immunity. Among these, the co-stimulatory receptor 4-1BB (CD137/TNFSF9) possesses an unequaled capacity for both activation and pro-inflammatory polarization of anti-tumor lymphocytes. While functional studies of 4-1BB have focused on its prominent role in augmenting cytotoxic CD8 T cells, 4-1BB can also modulate the activity of CD4 T cells, B cells, natural killer cells, monocytes, macrophages, and dendritic cells. 4-1BB's expression on both T cells and antigen presenting cells, coupled with its capacity to promote survival, expansion, and enhanced effector function of activated T cells, has made it an alluring target for tumor immunotherapy. In contrast to immune checkpoint blocking antibodies, 4-1BB agonists can both potentiate anti-tumor and anti-viral immunity, while at the same time ameliorating autoimmune disease. Despite this, 4-1BB agonists can trigger high grade liver inflammation which has slowed their clinical development. In this review, we discuss how the underlying immunobiology of 4-1BB activation suggests the potential for therapeutically synergistic combination strategies in which immune adverse events can be minimized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., & Chen, L. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1396 · Cited by 363
4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O., & Kwon, B. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4882 · Cited by 363
Clinical effects and toxicity of interleukin-2 in patients with cancer
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z · Cited by 355
Immunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 342
4-1BB-mediated immunotherapy of rheumatoid arthritis
Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S., & Kwon, B. S. (2004) · Nature Medicine · doi:10.1038/nm1107 · Cited by 325
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Weber, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 286
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006682 · Cited by 281
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
Bertram, E. M., Lau, P., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3777 · Cited by 265
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Hurtado, J. C., Kim, Y. J., & Kwon, B. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 257
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S., Kellett, M., Ruzevick, J., Jackson, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 244
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214184 · Cited by 222
Immune Responses in 4-1BB (CD137)-Deficient Mice
Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E., & Vinay, D. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5483 · Cited by 221
Melero, I., Bach, N., Hellström, K. E., Aruffo, A., Mittler, R. S., & Chen, L. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199803)28:03<1116::aid-immu1116>3.0.co;2-a · Cited by 217
Maniar, A., Zhang, X., Lin, W., Gastman, B. R., Pauza, C. D., Strome, S. E., & Chapoval, A. I. (2010) · Blood · doi:10.1182/blood-2009-07-234211 · Cited by 214
Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019499 · Cited by 213
Self-citationSun, Y., Lin, X., Chen, H. M., Wu, Q., Subudhi, S. K., Chen, L., & Fu, Y.-X. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1457 · Cited by 189
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
Curran, M. A., Geiger, T. L., Montalvo, W., Kim, M., Reiner, S. L., Al-Shamkhani, A., Sun, J. C., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121190 · Cited by 187
Self-citationPalazón, A., Martínez-Forero, I., Teijeira, A., Morales-Kastresana, A., Alfaro, C., Sanmamed, M. F., Perez-Gracia, J. L., Peñuelas, I., Hervás-Stubbs, S., Rouzaut, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0314 · Cited by 187
Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Human 4-1BB (CD137) Signals Are Mediated by TRAF2 and Activate Nuclear Factor-κB
Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H., & Kwon, B. S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8016 · Cited by 176
Foell, J. L., Strahotin, S., O’Neil, S. P., McCausland, M. M., Suwyn, C. R., Haber, M., Chander, P. N., Bapat, A. S., Yan, X., Chiorazzi, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17662 · Cited by 176
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells
Choi, B. K., Bae, J. S., Choi, E. M., Kang, W. J., Sakaguchi, S., Vinay, D. S., & Kwon, B. S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1003491 · Cited by 175
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
Sabbagh, L., Pulle, G., Liu, Y., Tsitsikov, E. N., & Watts, T. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8093 · Cited by 167
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
Moran, A. E., Kovacsovics-Bankowski, M., & Weinberg, A. D. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.004 · Cited by 162
Qui, H. Z., Hagymasi, A. T., Bandyopadhyay, S., St. Rose, M.-C., Ramanarasimhaiah, R., Ménoret, A., Mittler, R. S., Gordon, S. M., Reiner, S. L., Vella, A. T., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101244 · Cited by 158
Elpek, K. G., Yolcu, E. S., Franke, D. D. H., Lacelle, C., Schabowsky, R.-H., & Shirwan, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7295 · Cited by 154
4-1BB signaling beyond T cells
Vinay, D. S., & Kwon, B. S. (2011) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.82 · Cited by 149
Schoenbrunn, A., Frentsch, M., Köhler, S., Keye, J., Dooms, H., Moewes, B., Dong, J., Loddenkemper, C., Sieper, J., Wu, P., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201090 · Cited by 148
4-1BB and OX40 Act Independently to Facilitate Robust CD8 and CD4 Recall Responses
Dawicki, W., Bertram, E. M., Sharpe, A. H., & Watts, T. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5944 · Cited by 147
Immune regulation and control of regulatory T cells by OX40 and 4-1BB
So, T., Lee, S., & Croft, M. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.003 · Cited by 145
Palazón, A., Teijeira, Á., Martínez‐Forero, I., Hervás‐Stubbs, S., Roncal, C., Peñuelas, I., Dubrot, J., Morales‐Kastresana, A., Perez‐Gracia, J. L., Ochoa, M. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1733 · Cited by 143
Hernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 139
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Houot, R., Goldstein, M. J., Kohrt, H. E. K., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223958 · Cited by 135
Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
Madireddi, S., Eun, S.-Y., Lee, S., Nemčovičová, I., Mehta, A. K., Zajonc, D. M., Nishi, N., Niki, T., Hirashima, M., & Croft, M. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132687 · Cited by 128
Huang, J.-H., Zhang, S.-N., Choi, K., Choi, I.-K., Kim, J.-H., Lee, M., Kim, H., & Yun, C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.205 · Cited by 124
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Berezhnoy, A., Castro, I., Levay, A. K., Malek, T. R., & Gilboa, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69856 · Cited by 123
May, K. F., Chen, L., Zheng, P., & Liu, Y. (2002) · PubMed · Cited by 122
Martinet, O., Ermekova, V., Qiao, J. Q., Sauter, B., Mandeli, J., Chen, L., & Chen, S. H. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.931 · Cited by 122
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 121
Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses
Lee, S., Park, Y., Song, A., Cheroutre, H., Kwon, B. S., & Croft, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4464 · Cited by 120
CD137 (4–1BB) Deficiency Reduces Atherosclerosis in Hyperlipidemic Mice
Jeon, H. J., Choi, J., Jung, I., Park, J., Lee, M., Lee, M.-N., Kim, B., Yoo, J. Y., Jeong, S., Kim, D.-Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.882704 · Cited by 120
Lee, S., Myers, L. M., Muralimohan, G., Dai, J., Qiao, Y., Li, Z., Mittler, R. S., & Vella, A. T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3002 · Cited by 120
Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martínez‐Forero, I., Perez‐Gracia, J. L., Morales‐Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás‐Stubbs, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0846-9 · Cited by 115
Cooper, D. A., Bansal‐Pakala, P., & Croft, M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200202)32:2<521::aid-immu521>3.0.co;2-x · Cited by 114
John, L. B., Howland, L. J., Flynn, J. K., West, A. C., Devaud, C., Duong, C. P. M., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2788 · Cited by 113
Expression and function of 4‐1BB during CD4 versus CD8 T cell responses in vivo
Dawicki, W., & Watts, T. H. (2004) · European Journal of Immunology · doi:10.1002/eji.200324278 · Cited by 112
Xu, D., Gu, P., Pan, P., Li, Q., Sato, A. I., & Chen, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.11696 · Cited by 110
Drenkard, D., Becke, F. M., Langstein, J., Spruß, T., Kunz‐Schughart, L. A., Tan, T. E., Lim, Y. C., & Schwarz, H. (2006) · The FASEB Journal · doi:10.1096/fj.05-4739com · Cited by 110
Wei, H., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, M., Hellström, I., Hellström, K. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084927 · Cited by 107
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Weber, J. S. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-16 · Cited by 107
CD137 Expression in Tumor Vessel Walls
Broll, K., Richter, G., Pauly, S., Hofstaedter, F., & Schwarz, H. (2001) · American Journal of Clinical Pathology · doi:10.1309/e343-kmyx-w3y2-10ky · Cited by 103
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A. J., Levay, A. K., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 98
Guo, Z., Cheng, D., Xia, Z., Luan, M., Wu, L., Wang, G., & Zhang, S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-215 · Cited by 95
Cuadros, C., Dominguez, A. L., Lollini, P., Croft, M., Mittler, R. S., Borgström, P., & Lustgarten, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21098 · Cited by 91
Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., et al. (2015) · PubMed · Cited by 90
Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease
Lin, G. H. Y., Sedgmen, B. J., Moraes, T. J., Snell, L. M., Topham, D. J., & Watts, T. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.934 · Cited by 90
Pauly, S., Broll, K., Wittmann, M., Giegerich, G., & Schwarz, H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.35 · Cited by 88
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
Shi, W., & Siemann, D. W. (2006) · PubMed · Cited by 88
Lee, S., Park, Y., So, T., Kwon, B. S., Cheroutre, H., Mittler, R. S., & Croft, M. (2008) · Nature Immunology · doi:10.1038/ni.1632 · Cited by 87
Chen, S., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L., Mittler, R. S., & Woo, S. L. C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0086 · Cited by 87
Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors
Gilboa, E., McNamara, J. O., & Pastor, F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2067 · Cited by 85
Sharma, R. K., Elpek, K. G., Yolcu, E. S., Schabowsky, R.-H., Zhao, H., Bandura‐Morgan, L., & Shirwan, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3141 · Cited by 82
CD137 Promotes Proliferation and Survival of Human B Cells
Zhang, X., Voskens, C., Sallin, M. A., Maniar, A., Montes, C. L., Zhang, Y., Lin, W., Li, G., Burch, E. E., Tan, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901619 · Cited by 81
Nishimoto, H., Lee, S., Hong, H., Potter, K. G., Maeda‐Yamamoto, M., Kinoshita, T., Kawakami, Y., Mittler, R. S., Kwon, B. S., Ware, C. F., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1358 · Cited by 79
Choi, B. K., Asai, T., Vinay, D. S., Kim, Y. H., & Kwon, B. S. (2006) · Cytokine · doi:10.1016/j.cyto.2006.04.008 · Cited by 73
Martínez‐Forero, I., Azpilikueta, A., Bolaños, E., Nistal‐Villán, E., Palazón, A., Teijeira, Á., Pérez-Chacón, G., Morales‐Kastresana, A., Murillo, O., Jure‐Kunkel, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203010 · Cited by 73
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H., Shin, S. M., Yokoyama, W. M., Kim, T. Y., & Kwon, B. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1056 · Cited by 72
Ho, W. T., Pang, W. L., Chong, S. M., Castella, A., Al‐Salam, S., Tan, T. E., Moh, M. C., Koh, L. K., Gan, S. U., Cheng, C. K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3849 · Cited by 72
Wang, J., Zhao, W., Cheng, L., Guo, M., Li, D., Li, X., Tan, Y. J., Ma, S., Li, S., Yang, Y., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000927 · Cited by 70
Tirapu, I., Arina, A., Mazzolini, G. D., Duarte, M. C., Alfaro, C., Feijoó, E., Qian, C., Chen, L., Prìeto, J., & Melero, I. (2004) · International Journal of Cancer · doi:10.1002/ijc.20093 · Cited by 69
Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model
Newcomb, E. W., Lukyanov, Y., Kawashima, N., Alonso‐Basanta, M., Wang, S., Liu, M., Jure‐Kunkel, M., Zagzag, D., Demaria, S., & Formenti, S. C. (2010) · Radiation Research · doi:10.1667/rr1904.1 · Cited by 68
Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells
Wang, J., Guo, Z., Dong, Y., Kim, O., Hart, J. A. L., Adams, A. B., Larsen, C. P., Mittler, R. S., & Newell, K. A. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00088.x · Cited by 67
Lotze, M. T., & Rosenberg, S. A. (1986) · Immunobiology · doi:10.1016/s0171-2985(86)80122-x · Cited by 66
Kim, D., Chang, W., Lee, Y. S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2062 · Cited by 65
Han, X., Huang, B., Yuan, Y., Li, D., Han, L., Liu, Y., Gong, W., Wu, F., Zhang, G., & Feng, Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2154 · Cited by 65
Li, B., Lin, J., VanRoey, M. J., Jure‐Kunkel, M., & Jooss, K. U. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.07.005 · Cited by 63
Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
Gauttier, V., Judor, J., Guen, V. L., Cany, J., Ferry, N., & Conchon, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.28943 · Cited by 62
Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells
Lee, S., Salek‐Ardakani, S., Mittler, R. S., & Croft, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803241 · Cited by 62
Sharma, R. K., Schabowsky, R.-H., Srivastava, A. K., Elpek, K. G., Madireddi, S., Zhao, H., Zhong, Z., Miller, R. W., MacLeod, K. J., Yolcu, E. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4480 · Cited by 61
Biphasic role of 4‐1BB in the regulation of mouse cytomegalovirus‐specific CD8+ T cells
Humphreys, I. R., Lee, S., Jones, M., Loewendorf, A. I., Emma Gostick, D., Price, D. A., Benedict, C. A., Ware, C. F., & Croft, M. (2010) · European Journal of Immunology · doi:10.1002/eji.200940256 · Cited by 60
Kim, C.-S., Kim, J. G., Lee, B.-J., Choi, M., Choi, H., Kawada, T., Lee, K., & Yu, R. (2011) · Diabetes · doi:10.2337/db10-1805 · Cited by 60
Quetglas, J. I., Dubrot, J., Bezunartea, J., Sanmamed, M. F., Hervás‐Stubbs, S., Smerdou, C., & Melero, I. (2012) · Molecular Therapy · doi:10.1038/mt.2012.56 · Cited by 59
Zhang, B., Maris, C. H., Foell, J. L., Whitmire, J. K., Niu, L., Song, J., Kwon, B. S., Vella, A. T., Ahmed, R., Jacob, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32426 · Cited by 59
Enhanced CD4 T Cell Responsiveness in the Absence of 4-1BB
Lee, S., Vella, A. T., Kwon, B. S., & Croft, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6803 · Cited by 59
Kim, Y. H., Choi, B. K., Kim, K. H., Kang, S. W., & Kwon, B. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1365 · Cited by 59
NF‐κB and AP‐1 regulate activation‐dependent CD137 (4‐1BB) expression in T cells
Kim, J., Kim, H. W., Baek, K., & Kang, C. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00326-0 · Cited by 58
Schabowsky, R.-H., Elpek, K. G., Madireddi, S., Sharma, R. K., Yolcu, E. S., Bandura‐Morgan, L., Miller, R. E., MacLeod, K. J., Mittler, R. S., & Shirwan, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.127 · Cited by 58
Lee, J., Lee, E.-N., Kim, E. Y., Park, H.-J., Chang, C.-Y., Jung, D.-Y., Choi, S.-Y., Lee, S., Lee, K.-W., Kwon, G.-Y., et al. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.001 · Cited by 58
Blocking 4-1BB/4-1BB Ligand Interactions Prevents Herpetic Stromal Keratitis
Seo, S. K., Park, H. Y., Choi, J., Kim, W. Y., Kim, Y. H., Jung, H. W., Kwon, B., Lee, H. W., & Kwon, B. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.576 · Cited by 57
Modulating Protective and Pathogenic CD4+ Subsets via CD137 in Type 1 Diabetes
Irie, J., Wu, Y., Kachapati, K., Mittler, R. S., & Ridgway, W. M. (2006) · Diabetes · doi:10.2337/db06-0793 · Cited by 57
Pan, P., Gu, P., Li, Q., Xu, D., Weber, K. J., & Chen, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4779 · Cited by 56
Gong, W., Xiao, W., Hu, M., Weng, X., Li, Q., Pan, X., & Ming-chun, J. (2010) · Tissue Antigens · doi:10.1111/j.1399-0039.2010.01535.x · Cited by 56
Lee, D. Y., Choi, B. K., Lee, D. G., Kim, Y. H., Kim, C. H., Lee, S. J., & Kwon, B. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069677 · Cited by 56
4-1BB Chimeric Antigen Receptors
Campana, D., Schwarz, H., & Imai, C. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000028 · Cited by 54
Cannons, J. L., Chamberlain, G., Howson, J. M. M., Smink, L. J., Todd, J. A., Peterson, L. B., Wicker, L. S., & Watts, T. H. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.04.007 · Cited by 54
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas
Anderson, M. W., Zhao, S., Freud, A. G., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.015 · Cited by 53
CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells
Teijeira, Á., Palazón, A., Garasa, S., Marré, D., Aubá, C., Rogel, A., Murillo, O., Martínez‐Forero, I., Lang, F., Melero, I., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201061 · Cited by 53
Kim, Y. H., Choi, B. K., Shin, S. M., Kim, C. H., Oh, H. S., Park, S. H., Lee, D. G., Lee, M. J., Kim, K. H., Vinay, D. S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002681 · Cited by 53
Kim, H. S., Kim‐Schulze, S., Kim, D. W., & Kaufman, H. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2522 · Cited by 52
In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb
Murillo, O., Dubrot, J., Palazón, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838958 · Cited by 51
Ju, S., Lee, S., Kwon, T., Heo, S., Park, S., Paek, H., Suh, J., Cho, H. R., Kwon, B., Kwon, B. S., et al. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01330.x · Cited by 51
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Kim, Y. H., Choi, B. K., Oh, H. S., Kang, W. J., Mittler, R. S., & Kwon, B. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0993 · Cited by 50
Xu, D.-P., Sauter, B. V., Huang, T.-G., Meseck, M. L., Woo, S. L. C., & Chen, S. H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302556 · Cited by 48
Immune checkpoint combinations from mouse to man
Ai, M., & Curran, M. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1650-8 · Cited by 47
Self-citationKeersmaecker, B. D., Heirman, C., Corthals, J., Empsen, C., van Grunsven, L. A., Allard, S. D., Pen, J. J., Lacor, P., Thielemans, K., & Aerts, J. L. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0810466 · Cited by 47
Williams, E. L., Dunn, S. N., James, S., Johnson, P., Cragg, M. S., Glennie, M. J., & Gray, J. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3226 · Cited by 47
4-1BB (CD137) Is Required for Rapid Clearance ofListeria monocytogenesInfection
Lee, S.-C., Ju, S., Pack, H.-N., Heo, S.-K., Suh, J. H., Park, S.-M., Choi, B.-K., Kwon, B. S., & Kim, B. S. (2005) · Infection and Immunity · doi:10.1128/iai.73.8.5144-5151.2005 · Cited by 46
Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment
Yang, Y., Yang, S., Ye, Z., Jaffar, J., Zhou, Y., Cutter, E., Lieber, A., Hellström, I., & Hellström, K. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3593 · Cited by 45
Dubrot, J., Palazón, A., Alfaro, C., Azpilikueta, A., Ochoa, M. C., Rouzaut, A., Martínez‐Forero, I., Teijeira, Á., Berraondo, P., Bon, A. L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25333 · Cited by 44
Lin, G. H. Y., Snell, L. M., Wortzman, M. E., Clouthier, D., & Watts, T. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201854 · Cited by 44
Ju, S., Cheon, S., Park, S., Tam, N. Q., Kim, Y. M., An, W. G., & Kim, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23457 · Cited by 43
Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: Modulation by FGF‐2
Reali, C., Curto, M., Sogos, V., Scintu, F., Pauly, S., Schwarz, H., & Gremo, F. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10727 · Cited by 43
Sharma, R. K., Srivastava, A. K., Yolcu, E. S., MacLeod, K. J., Schabowsky, R.-H., Madireddi, S., & Shirwan, H. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.073 · Cited by 39
Strome, S. E., Martin, B. A., Flies, D. B., Tamada, K., Chapoval, A. I., Sargent, D. J., Shu, S., & Chen, L. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00006 · Cited by 39
Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
Youlin, K., Li, Z., Xiaodong, W., Xiuheng, L., & Hengchen, Z. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/439235 · Cited by 36
Tu, T. H., Kim, C.-S., Goto, T., Kawada, T., Kim, B.-S., & Yu, R. (2012) · Mediators of Inflammation · doi:10.1155/2012/972629 · Cited by 36
Morales‐Kastresana, A., Catalán, E., Hervás‐Stubbs, S., Palazón, A., Azpilikueta, A., Bolaños, E., Anel, A., Pardo, J., & Melero, I. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-3 · Cited by 35
Lee, S., Park, Y., Eun, S.-Y., Madireddi, S., Cheroutre, H., & Croft, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201248 · Cited by 35
Jiang, D., & Schwarz, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015565 · Cited by 33
Sytwu, H., Lin, W., Roffler, S. R., Hung, J., Sung, H.-S., Wang, C., Cheng, T., Tsou, S.-C., Hsi, S., & Shen, K. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00112-4 · Cited by 33
Lee, S. J., Kim, Y. H., Hwang, S. H., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242842 · Cited by 31
Inhibition of Th2-Mediated Allergic Airway Inflammatory Disease by CD137 Costimulation
Sun, Y., Blink, S. E., Liu, W., Lee, Y., Chen, B., Solway, J., Weinstock, J. V., Chen, L., & Fu, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.814 · Cited by 29
Choi, B. K., Lee, S. C., Lee, M. J., Kim, Y. H., Kim, Y., Ryu, K. W., Lee, J., Shin, S. M., Lee, S. H., Suzuki, S., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000027 · Cited by 29
Vidric, M., Suh, W., Dianzani, U., Mak, T. W., & Watts, T. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7288 · Cited by 27
Srivastava, A. K., Sharma, R. K., Yolcu, E. S., Ulker, V., MacLeod, K. J., Dinc, G., & Shirwan, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048463 · Cited by 27
Lee, S., Ju, S., Sung, B.-H., Heo, S., Cho, H. R., Lee, E. A., Kim, J. D., Lee, I. H., Park, S.-M., Nguyen, Q. T., et al. (2009) · Infection and Immunity · doi:10.1128/iai.01350-08 · Cited by 27
Foell, J. L., McCausland, M. M., BURCH, J., CORRIAZZI, N., Yan, X., Suwyn, C. R., O’Neil, S. P., Hoffmann, M. K., & Mittler, R. S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06052.x · Cited by 26
Moraes, T. J., Lin, G. H. Y., Wen, T., & Watts, T. H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.022 · Cited by 26
Rose, M. S., Taylor, R. A., Bandyopadhyay, S., Qui, H. Z., Hagymasi, A. T., Vella, A. T., & Adler, A. J. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2012.74 · Cited by 23
Li, Y., Yan, J., Wu, C., Wang, Z., Yuan, W., & Wang, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088563 · Cited by 21
Induction of 4‐1BB (CD137) expression by DNA damaging agents in human T lymphocytes
Kim, K., Kim, H. W., Kim, J., Baek, K., Kim, J. G., & Kang, C. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01538.x · Cited by 21
Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells
Goldstein, M. J., Kohrt, H. E. K., Houot, R., Varghese, B., Lin, J. T., Swanson, E., & Levy, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3375 · Cited by 21
Self-Antigen Prevents CD8 T Cell Effector Differentiation by CD134 and CD137 Dual Costimulation
Bandyopadhyay, S., Long, M., Qui, H. Z., Hagymasi, A. T., Slaiby, A. M., Mihalyo, M. A., Aguila, H. L., Mittler, R. S., Vella, A. T., & Adler, A. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7728 · Cited by 20
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation
Shin, S. M., Kim, Y. H., Choi, B. K., Kwon, P. M., Lee, H., & Kwon, B. S. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1006619 · Cited by 20
Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses
Kim, J., Choi, S. P., La, S., Seo, J., Kim, K. K., Nam, S. H., & Kwon, B. (2003) · Experimental & Molecular Medicine · doi:10.1038/emm.2003.66 · Cited by 20
Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells
Zhao, Y., & Croft, M. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.10.008 · Cited by 18
Li, G., Wu, X., Zhang, F., Li, X., Sun, B., Yu, Y., Yin, A., Deng, L., Yin, J., & Wang, X. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0905-9 · Cited by 18
Kim, Y. H., Choi, B. K., Kang, W. J., Kim, K. H., Kang, S. W., Mellor, A. L., Munn, D. H., & Kwon, B. S. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0408246 · Cited by 18
Yang, J., Park, O.-J., Lee, Y. J., Jung, H., Woo, K. M., & Choi, Y. (2008) · European Journal of Immunology · doi:10.1002/eji.200737650 · Cited by 17
Lin, X., Zhou, C., Wang, S., Wang, D., Ma, W., Liang, X., Lin, C., Wang, Z., Li, J., Guo, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22048 · Cited by 17
Blockade of 4-1BB and 4-1BBL Interaction Reduces Obesity-Induced Skeletal Muscle Inflammation
Ngoc, H. L., Kim, C.-S., Tu, T. H., Choi, H., Kim, B.-S., Kawada, T., Goto, T., Park, T., Park, J. H. Y., & Yu, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/865159 · Cited by 16
Activation of c-Jun N-terminal Kinase by 4-1BB (CD137), a T Cell Co-stimulatory Molecule
Kim, H., Kwack, K., & Lee, Z. H. (2000) · Molecules and Cells · doi:10.1016/s1016-8478(23)17471-1 · Cited by 16
Vinay, D. S., Lee, S. J., Kim, C. H., Oh, H. S., & Kwon, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050272 · Cited by 15
Zhang, H., Knutson, K. L., Hellström, K. E., Disis, M. L., & Hellström, I. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0206 · Cited by 15
Choi, B. K., Kim, Y. H., Choi, J., Kim, C. H., Kim, K., Sung, Y., Lee, Y. M., Moffett, J. R., & Kwon, B. S. (2011) · Cytokine · doi:10.1016/j.cyto.2011.05.015 · Cited by 10
4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo
Li, Q., Ai, J., Song, Z., Liu, J., & Shan, B. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.47 · Cited by 10
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
Quetglas, J. I., John, L. B., Kershaw, M. H., Álvarez‐Vallina, L., Melero, I., Darcy, P. K., & Smerdou, C. (2012) · OncoImmunology · doi:10.4161/onci.21679 · Cited by 9
Shi, Y., Hu, S., Song, Q., Yu, S., Zhou, X., Yin, J., Qin, L., & Qian, H. (2013) · BioMed Research International · doi:10.1155/2013/192738 · Cited by 5
Cited by
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Metadata
- Authors
- Bartkowiak, T., & Curran, M. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-06-08
- Volume
- 5
- Pages
- 117-117
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1512799118
- Cited by
- 256
- References
- 171
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.